Effect of medication adherence on clinical outcomes in type 2 diabetes: analysis of the SIMPLE study.

Patel S, Abreu M, Tumyan A, Adams-Huet B, Li X, Lingvay I

BMJ open diabetes research & care18 Nov 2019Cited by 49 (Europe PMC)

PMID31803482PMCIDPMC6887507DOI10.1136/bmjdrc-2019-000761PepBankPUB-31803482

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneRandomized controlled trialOther
In adults with very uncontrolled type 2 diabetes, more participants on detemir plus liraglutide than on basal-bolus insulin had 80% or more adherence to detemir.
In plain wordsIn adults with very uncontrolled type 2 diabetes, more people on detemir plus liraglutide took their detemir as planned than people on basal-bolus insulin.
Peptide
Liraglutide
Outcome
IncreaseAdherence to detemir (80% or more)
Study
n = 120
Comparator
Basal-bolus insulin (detemir plus aspart)
Outcome group
Treatment adherence and retention · Metabolic and weight
Measurements
Adherence 80% or more
59.3%
detemir plus liraglutide
Adherence 80% or more
35.7%
basal-bolus insulin
Source sentences
Summary
A higher percentage of participants in the GLP1RA+BI compared with the BBI group had ≥80% adherence to detemir (59.3% vs 35.7%, p=0.02) as well as liraglutide versus aspart (57.4% vs 30.4%, p=0.007).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 120 adults with T2DM and HgbA1c≥10% were randomized to detemir plus liraglutide, or detemir plus aspart before each meal; 6-month follow-up.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3180348201
02HumanNot a test of Liraglutide aloneRandomized controlled trialOther
In adults with very uncontrolled type 2 diabetes, 57.4% adhered at 80% or more to liraglutide in the combined regimen, versus 30.4% to aspart in basal-bolus insulin.
In plain wordsIn adults with very uncontrolled type 2 diabetes, more people took liraglutide as planned than took aspart in the basal-bolus regimen.
Peptide
Liraglutide
Outcome
IncreaseAdherence to liraglutide versus aspart (80% or more)
Study
n = 120
Comparator
Basal-bolus insulin (detemir plus aspart)
Outcome group
Treatment adherence and retention · Metabolic and weight
Measurements
Adherence 80% or more
57.4%
liraglutide
Adherence 80% or more
30.4%
aspart
Source sentences
Summary
A higher percentage of participants in the GLP1RA+BI compared with the BBI group had ≥80% adherence to detemir (59.3% vs 35.7%, p=0.02) as well as liraglutide versus aspart (57.4% vs 30.4%, p=0.007).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 120 adults with T2DM and HgbA1c≥10% were randomized to detemir plus liraglutide, or detemir plus aspart before each meal; 6-month follow-up.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3180348202
03HumanNot a test of Liraglutide aloneRandomized controlled trialOther
In adults with very uncontrolled type 2 diabetes, higher age predicted 80% or more adherence across both regimens.
In plain wordsIn adults with very uncontrolled type 2 diabetes, older age was linked to better adherence to the treatment.
Peptide
Liraglutide
Outcome
IncreaseBaseline predictor of adherence: age
Study
n = 120
Outcome group
Treatment adherence and retention · Metabolic and weight
Measurements
Odds ratio per 5-year increment
1.48 OR
age
Source sentences
Summary
Higher age was predictive of ≥80% adherence (OR per 5-year increment=1.48, 95% CI 1.09 to 2.0, p=0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 120 adults with T2DM and HgbA1c≥10% were randomized to detemir plus liraglutide, or detemir plus aspart before each meal; 6-month follow-up.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3180348203
04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with very uncontrolled type 2 diabetes, higher adherence led to greater HbA1c improvement in both regimen groups.
In plain wordsIn adults with very uncontrolled type 2 diabetes, better adherence was linked to larger improvement in HbA1c in both groups.
Peptide
Liraglutide
Outcome
DecreaseHbA1c improvement with higher adherence
Study
n = 120
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Higher adherence led to greater improvement in HbA1c and weight in both groups.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 120 adults with T2DM and HgbA1c≥10% were randomized to detemir plus liraglutide, or detemir plus aspart before each meal; 6-month follow-up.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3180348204
05HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with very uncontrolled type 2 diabetes, higher adherence led to greater weight improvement in both regimen groups.
In plain wordsIn adults with very uncontrolled type 2 diabetes, better adherence was linked to larger weight improvement in both groups.
Peptide
Liraglutide
Outcome
DecreaseWeight improvement with higher adherence
Study
n = 120
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Higher adherence led to greater improvement in HbA1c and weight in both groups.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 120 adults with T2DM and HgbA1c≥10% were randomized to detemir plus liraglutide, or detemir plus aspart before each meal; 6-month follow-up.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3180348205
06HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with very uncontrolled type 2 diabetes, detemir plus liraglutide led to greater HbA1c improvement than basal-bolus insulin, also after adjustment for adherence.
In plain wordsIn adults with very uncontrolled type 2 diabetes, a detemir plus liraglutide regimen improved HbA1c more than basal-bolus insulin.
Peptide
Liraglutide
Outcome
DecreaseHbA1c, detemir plus liraglutide versus basal-bolus insulin
Study
n = 120
Comparator
Basal-bolus insulin (detemir plus aspart)
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Treatment with GLP1RA+BI compared with BBI led to greater improvement in HbA1c, weight, and quality of life and lower risk of hypoglycemia even after adjusting for the difference in adherence between groups.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 120 adults with T2DM and HgbA1c≥10% were randomized to detemir plus liraglutide, or detemir plus aspart before each meal; 6-month follow-up.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3180348206
07HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with very uncontrolled type 2 diabetes, detemir plus liraglutide led to greater weight improvement than basal-bolus insulin, also after adjustment for adherence.
In plain wordsIn adults with very uncontrolled type 2 diabetes, a detemir plus liraglutide regimen improved weight more than basal-bolus insulin.
Peptide
Liraglutide
Outcome
DecreaseWeight, detemir plus liraglutide versus basal-bolus insulin
Study
n = 120
Comparator
Basal-bolus insulin (detemir plus aspart)
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Treatment with GLP1RA+BI compared with BBI led to greater improvement in HbA1c, weight, and quality of life and lower risk of hypoglycemia even after adjusting for the difference in adherence between groups.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 120 adults with T2DM and HgbA1c≥10% were randomized to detemir plus liraglutide, or detemir plus aspart before each meal; 6-month follow-up.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3180348207
08HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with very uncontrolled type 2 diabetes, detemir plus liraglutide led to greater improvement in quality of life than basal-bolus insulin, also after adjustment for adherence.
In plain wordsIn adults with very uncontrolled type 2 diabetes, a detemir plus liraglutide regimen improved quality of life more than basal-bolus insulin.
Peptide
Liraglutide
Outcome
IncreaseQuality of life, detemir plus liraglutide versus basal-bolus insulin
Study
n = 120
Comparator
Basal-bolus insulin (detemir plus aspart)
Outcome group
Quality of life · Metabolic and weight
Source sentences
Summary
Treatment with GLP1RA+BI compared with BBI led to greater improvement in HbA1c, weight, and quality of life and lower risk of hypoglycemia even after adjusting for the difference in adherence between groups.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 120 adults with T2DM and HgbA1c≥10% were randomized to detemir plus liraglutide, or detemir plus aspart before each meal; 6-month follow-up.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3180348208
09HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome
In adults with very uncontrolled type 2 diabetes, detemir plus liraglutide led to lower risk of hypoglycemia than basal-bolus insulin, also after adjustment for adherence.
In plain wordsIn adults with very uncontrolled type 2 diabetes, a detemir plus liraglutide regimen had a lower risk of low blood sugar than basal-bolus insulin.
Peptide
Liraglutide
Outcome
DecreaseHypoglycemia risk, detemir plus liraglutide versus basal-bolus insulin
Study
n = 120
Comparator
Basal-bolus insulin (detemir plus aspart)
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
Treatment with GLP1RA+BI compared with BBI led to greater improvement in HbA1c, weight, and quality of life and lower risk of hypoglycemia even after adjusting for the difference in adherence between groups.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 120 adults with T2DM and HgbA1c≥10% were randomized to detemir plus liraglutide, or detemir plus aspart before each meal; 6-month follow-up.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3180348209

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT01966978

The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study

University of Texas Southwestern Medical Centern = 157Nov 2014 to Dec 2017

Diabetes Mellitus, Type 2 · Diabetes

Trial page ClinicalTrials.govUpdated 22 Oct 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.